Company news

Share this article:
Merck said it will retain its interest in certain AstraZeneca non-heartburn drugs, which means in 2012 AstraZeneca can buy out an interest Merck holds in its heartburn drugs, including blockbuster medication Nexium. The two companies have been partnering in a long-running joint venture. Last month, Merck said it expected its full-year 2008 earnings to include a gain of about $2.2 billion, as AstraZeneca begins to buy out Merck's share in the joint venture.  Merck said it will receive payments from AstraZeneca in the first quarter of 2008 in the amount of $2.6 billion -- a payment of about $4.0 billion offset by a loan repayment of $1.4 billion. As a result of this decision, AstraZeneca will have its own option to buy Merck's interest in the non-heartburn, products in the first half of 2010, meaning the ownership would change hands. Sales of Nexium declined 9% to $1.3 billion in the fourth quarter and pressure is expected to increase with the arrival in the US of generic copies of rival heartburn drug Protonix, sold by US drug maker Wyeth.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.